山東威高集團醫用高分子製品股份有限公司（01066）于2025年11月21日发布翌日披露报表，显示公司在当日于香港联合交易所回购合共348,400股H股，占当日前已发行股本约0.0077%。本次回购价格区间为每股5.24港元至5.29港元，涉资约1,832,116港元。
回购完成后，公司已发行股本总数维持4,522,332,324股，其中流通股为4,495,949,524股，库藏股增加至26,382,800股。公司于2025年5月27日通过回购授权，总可回购股份数量为451,560,392股，截至本次交易后已累计回购19,734,400股，约占授权额度的4.3703%。
公司在公告中确认已遵守香港联合交易所的上市规则以及相关法律法规，并由公司秘書黃妙玲签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.